Frank Dörje

7PUBLICATIONS
24CO-AUTHORS
Gene and molecular therapyMolecular targetsPharmaceutical delivery technologiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 19, 2026
Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations.

|Dec 22, 2025
Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data.

Michael I Sponfeldner, Pauline Dürr, Phyllis Lensker

|Jul 18, 2025
Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics.

Lisa Cuba, Frank Dörje, Rafaela Kramer

|Jun 07, 2024
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.

Lisa Cuba, Pauline Dürr, Katja Gessner

|Apr 24, 2024
From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy.

Lisa Cuba, Pauline Dürr, Frank Dörje

|Mar 20, 2024
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial.

Johannes Plechschmidt, Konstantin Fietkau, Tobias Hepp

Pageof 2

Frequent Collaborators

5 joint publications

Lisa Cuba

5 joint publications

Pauline Dürr

5 joint publications

Martin F Fromm

3 joint publications

Katja Schlichtig